25.08.2020 • NewsBASFIdemitsu

BASF and Idemitsu End BDO JV

BASF, in mutual agreement with partner Idemitsu Kosan, has decided to end its joint-venture 1,4-butanediol (BDO) in Japan. Consequently, BASF Idemitsu’s BDO plant at Chiba, Japan, will close in December 2020. All 21 people employed at the plant will be offered alternative employment at either BASF or Idemitsu in Japan.

“The closure of the Chiba plant has become inevitable due to a declining BDO market size in Japan and significant overcapacities in Asia due to recent investments into new coal-based BDO production sites,” explained Masaru Saitoh, president of BASF Idemitsu.

China has become the world’s largest producer and consumer of BDO, adding much of the new capacity in recent years. However, the capacity increases has led to excess supply and lower prices for BDO.

BASF said its decision was part of an ongoing global review of long-term options for its options in the BDO value chain. The company added that it will continue to supply Japanese customers from its other BDO plants in Asia, North America and Europe.

 

Author: Elaine Burridge, Freelance Journalist

BASF, in mutual agreement with partner Idemitsu Kosan, is ending its...
BASF, in mutual agreement with partner Idemitsu Kosan, is ending its joint-venture 1,4-butanediol (BDO) in Japan because of the country’s declining market and significant overcapacity in Asia. Consequently, BASF Idemitsu’s BDO plant at Chiba, Japan, will close in December 2020. (c) BASF

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.